The brand name maker of the prescription drug Hytrin, Abbott, entered into an agreement with Geneva to keep Geneva’s generic version of Hytrin off the market. Geneva was paid a substantial amount of money by Abbott while Abbott continued to collect monopoly profits on its name brand drug. Because of federal regulatory system for new generic entry, Geneva effectively blocked the entry of other generic drug makers. The matter settled in conjunction with MDL litigation.